Literature DB >> 35119937

Antigen cross-presentation in young tumor-bearing hosts promotes CD8+ T cell terminal differentiation.

Ardiana Moustaki1, Jeremy Chase Crawford1, Shanta Alli1, Yiping Fan2, Shannon Boi1, Anthony E Zamora1, Natalie M N McDonald1,3, Gang Wu2, Joy Nakitandwe4, Scott Newman5, Scott Foy5, Antonina Silkov5, Paul G Thomas1, Alberto Pappo6, Michael A Dyer7,8, Elizabeth Stewart6,7, Sara Federico6, Ben Youngblood1.   

Abstract

The immune system undergoes a progressive functional remodeling with age. Understanding how age bias shapes antitumor immunity is essential in designing effective immunotherapies, especially for pediatric patients. Here, we explore antitumor CD8+ T cell responses generated in young (prepubescent) and adult (presenescent) mice. Using an MHCI-deficient tumor model, we observed that tumor-reactive CD8+ T cells expanded in young tumor-bearing (TB) mice acquired a terminally differentiated phenotype characterized by overexpression of inhibitory receptors and the transcription factor Tox1. Furthermore, tumor-infiltrating CD8+ T cells from young tumors yielded a poor cytokine response compared with CD8+ T cells infiltrating adult tumors. Young migratory dendritic cells (migDCs) from the draining lymph nodes (dLNs), and mononuclear phagocytic cells (MPCs) infiltrating young tumors, were more competent in capturing and cross-presenting tumor antigen, leading to enhanced priming of CD8+ T cells in dLNs and their subsequent terminal differentiation in the tumors. Single-cell transcriptional profiling of tumor-infiltrating MPCs demonstrated that young MPCs are polarized toward an inflammatory, effector phenotype. Consistent with our observations in young versus adult TB mice, analysis of immune infiltrates from pediatric solid tumors showed a correlation between tumor-infiltrating CD8+ T cells with an exhaustion phenotype and the frequency of PD-L1-expressing monocytes/macrophages. Collectively, these data indicate that a young tissue microenvironment contributes to the generation of an immune response skewed toward a less pliable terminal effector state, thus narrowing the window for immunotherapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35119937      PMCID: PMC8990347          DOI: 10.1126/sciimmunol.abf6136

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  65 in total

1.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.

Authors:  Ron Edgar; Michael Domrachev; Alex E Lash
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  Quantifiable predictive features define epitope-specific T cell receptor repertoires.

Authors:  Pradyot Dash; Andrew J Fiore-Gartland; Tomer Hertz; George C Wang; Shalini Sharma; Aisha Souquette; Jeremy Chase Crawford; E Bridie Clemens; Thi H O Nguyen; Katherine Kedzierska; Nicole L La Gruta; Philip Bradley; Paul G Thomas
Journal:  Nature       Date:  2017-06-21       Impact factor: 49.962

Review 3.  Requirements for CD8 T-cell priming, memory generation and maintenance.

Authors:  Martin Prlic; Matthew A Williams; Michael J Bevan
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

4.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen.

Authors:  H Pircher; K Bürki; R Lang; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

5.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

Authors:  Brian C Miller; Debattama R Sen; Rose Al Abosy; Kevin Bi; Yamini V Virkud; Martin W LaFleur; Kathleen B Yates; Ana Lako; Kristen Felt; Girish S Naik; Michael Manos; Evisa Gjini; Juhi R Kuchroo; Jeffrey J Ishizuka; Jenna L Collier; Gabriel K Griffin; Seth Maleri; Dawn E Comstock; Sarah A Weiss; Flavian D Brown; Arpit Panda; Margaret D Zimmer; Robert T Manguso; F Stephen Hodi; Scott J Rodig; Arlene H Sharpe; W Nicholas Haining
Journal:  Nat Immunol       Date:  2019-02-18       Impact factor: 25.606

6.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Authors:  Se Jin Im; Masao Hashimoto; Michael Y Gerner; Junghwa Lee; Haydn T Kissick; Matheus C Burger; Qiang Shan; J Scott Hale; Judong Lee; Tahseen H Nasti; Arlene H Sharpe; Gordon J Freeman; Ronald N Germain; Helder I Nakaya; Hai-Hui Xue; Rafi Ahmed
Journal:  Nature       Date:  2016-08-02       Impact factor: 49.962

Review 7.  The clearance of dead cells by efferocytosis.

Authors:  Emilio Boada-Romero; Jennifer Martinez; Bradlee L Heckmann; Douglas R Green
Journal:  Nat Rev Mol Cell Biol       Date:  2020-04-06       Impact factor: 94.444

Review 8.  The hallmarks of aging.

Authors:  Carlos López-Otín; Maria A Blasco; Linda Partridge; Manuel Serrano; Guido Kroemer
Journal:  Cell       Date:  2013-06-06       Impact factor: 41.582

9.  TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion.

Authors:  Hyungseok Seo; Joyce Chen; Edahí González-Avalos; Daniela Samaniego-Castruita; Arundhoti Das; Yueqiang H Wang; Isaac F López-Moyado; Romain O Georges; Wade Zhang; Atsushi Onodera; Cheng-Jang Wu; Li-Fan Lu; Patrick G Hogan; Avinash Bhandoola; Anjana Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-31       Impact factor: 12.779

10.  Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome.

Authors:  Michael Rusch; Joy Nakitandwe; Sheila Shurtleff; Scott Newman; Zhaojie Zhang; Michael N Edmonson; Matthew Parker; Yuannian Jiao; Xiaotu Ma; Yanling Liu; Jiali Gu; Michael F Walsh; Jared Becksfort; Andrew Thrasher; Yongjin Li; James McMurry; Erin Hedlund; Aman Patel; John Easton; Donald Yergeau; Bhavin Vadodaria; Ruth G Tatevossian; Susana Raimondi; Dale Hedges; Xiang Chen; Kohei Hagiwara; Rose McGee; Giles W Robinson; Jeffery M Klco; Tanja A Gruber; David W Ellison; James R Downing; Jinghui Zhang
Journal:  Nat Commun       Date:  2018-09-27       Impact factor: 14.919

View more
  1 in total

1.  KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.

Authors:  Heng Liu; Jianhuang Lin; Wei Zhou; Renyta Moses; Zhongping Dai; Andrew V Kossenkov; Ronny Drapkin; Benjamin G Bitler; Sergey Karakashev; Rugang Zhang
Journal:  Cancer Immunol Res       Date:  2022-08-03       Impact factor: 12.020

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.